BMO Capital Maintains Market Perform on Macrogenics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout maintains a Market Perform rating on Macrogenics (NASDAQ:MGNX) but lowers the price target from $8 to $5.
August 07, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital has maintained its Market Perform rating on Macrogenics but has lowered the price target from $8 to $5.
The lowering of the price target from $8 to $5 by BMO Capital suggests a less optimistic outlook for Macrogenics, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100